Treatment Decision-Making in PIK3CA-mut HR+/HER2- Breast Cancer: Key Tolerability Considerations
Panelists discuss strategies for patient education and monitoring hyperglycemia with PI3K inhibitors, including pre-treatment screening, baseline assessments, early recognition of adverse events, and supportive care measures such as dietary modifications, with Ms. Harrington sharing practical approaches and helpful resources; Dr Isaacs comments on potential differences in adverse event management, particularly hyperglycemia, between inavolisib, capivasertib, and alpelisib, offering practical advice for oncologists; and Dr Kaklamani explores how the varying safety profiles of these agents may influence treatment selection and sequencing, including the potential for inavolisib to become standard of care in the first-line PIK3CA-mutant setting and how this will affect PI3K inhibitor sequencing in later treatment lines.
Video content above is prompted by the following:
- Dr Kaklamani asks Ms. Harrington: How do you approach patient education and monitoring for hyperglycemia with PI3K inhibitors? Could you walk us through your practical strategies for:
- Pretreatment screening and baseline assessments
- Patient education about early recognition and management of adverse events
- Implementation of supportive care measures, including dietary modifications
- What resources have you found most helpful in supporting patients through these management approaches?
- Dr Kaklamani asks Dr Isaacs: Do you anticipate any differences in adverse event management, particularly hyperglycemia, between inavolisib, capivasertib, and alpelisib? What practical advice would you give to oncologists about monitoring and managing these adverse events as the PI3K inhibitor landscape evolves?
- Dr Kaklamani addresses: The varying safety profiles we're seeing across PI3K inhibitors— inavolisib, capivasertib, and alpelisib—raise interesting questions about treatment selection and sequencing.
- What patient factors might lead you to prefer one agent over another?
- Do you anticipate inavolisib becoming standard of care in the first-line PIK3CA-mutant setting?
- With inavolisib in the frontline setting, how might you approach sequencing other PI3K inhibitors, antibody-drug conjugates, and other options in later lines of treatment?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
